Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Voclosporin: Additional Ph IIb AURA-LV data

Additional data from the double-blind, international Phase IIb AURA-LV trial in 265 patients with active lupus nephritis showed that twice-daily 23.7 and 39.5 mg oral voclosporin plus

Read the full 275 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE